Find a Doctor

LT
Areas of Expertise

Louis Terriou

Hôpital Claude Huriez
Male

Bio

Louis Terriou is in Lille, France. They have been an author on 87 peer reviewed articles and participated in 1 clinical trial in the past 15 years.

Areas of Expertise

Contact

Lille, FR

Latest Advances

Latest Advance
Study
  • Condition: Immune Thrombocytopenia
  • Journal: American journal of hematology
  • Treatment Used: Rituximab
  • Number of Patients: 248
  • Published —
This study assessed the long-term safety and effectiveness of rituximab in adults with immune thrombocytopenia.
Latest Advance
Study
  • Condition: Paroxysmal Nocturnal Hemoglobinuria
  • Journal: Blood advances
  • Treatment Used: Ravulizumab
  • Number of Patients: 39
  • Published —
This study evaluated the effectiveness and safety of multiple doses and regimens of ravulizumab in paroxysmal nocturnal hemoglobinuria (hemoglobin in urine; PNH) naive to complement-inhibitor treatment.
Latest Advance
Study
  • Condition: Systemic lups erythematosus
  • Journal: Rheumatology (Oxford, England)
  • Treatment Used: Thrombopoietin-receptor agonists
  • Number of Patients: 18
  • Published —
This study evaluated the safety and efficacy of thrombopoietin-receptor agonists.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Participants: 500
  • Start Date: October 2016
ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease

All Publications
View All

Publication
Study
  • Journal: American journal of hematology
  • Published —
High dose Romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia.
Publication
Study
  • Journal: American journal of hematology
  • Published —
High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia.

Contact

Lille, FR

Insurance

Contact them to find out if they accept your insurance plan.